RxDoctor Payments Data

Lee Dinning, DO

Family Medicine · Washington, GANPI 1770945628

Payments from drug & device makers

$1,580in general payments, 2019–2025

Across 78 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$452
  • Novo Nordisk$404
  • Lilly USA, LLC$256
  • Boehringer Ingelheim$103
  • Exact Sciences$87
  • Sanofi-aventis U.S. LLC$84
  • plus $194 from 5 others

What the payments were for

  • Food & beverage$1,580100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,580 in reported general payments places this provider in the 65th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$10,479
Medicare patients
27
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban145$90,246
OzempicSemaglutide60$76,748
JardianceEmpagliflozin51$68,060
MounjaroTirzepatide29$35,754
TrulicityDulaglutide25$29,826
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,835
XareltoRivaroxaban45$11,677
FarxigaDapagliflozin Propanediol12$11,063
MyrbetriqMirabegron17$7,950
Tresiba Flextouch U-200Insulin Degludec14$7,881
DapagliflozinDapagliflozin Propanediol14$6,300
Breo ElliptaFluticasone/Vilanterol13$5,450
SymbicortBudesonide/Formoterol Fumarate14$3,953
Quetiapine Fumarate269$3,696
Gabapentin233$3,625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$404$76,74860 claims
Boehringer IngelheimJardiance$103$68,06051 claims
Lilly USA, LLCMounjaro, Trulicity$256$65,58154 claims
GSKTrelegy Ellipta, Breo Ellipta$69$19,28530 claims
AstraZenecaFarxiga, Symbicort$452$15,01626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Washington

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →